Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339170 | 0.83 | GAA (0.36) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5892255 | 0.81 | GAA (0.39) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3633847 | 0.80 | POLB (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2637224 | 0.80 | POLB (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2976621 | 0.77 | POLB (0.40) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6493288 | 0.76 | POLB (0.39) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4050 | 0.75 | POLB (0.44) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10006209 | 0.74 | POLB (0.38) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6483365 | 0.73 | CYP3A4 (0.39) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4283885 | 0.73 | LMNA (0.45) | POLBGAACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1502590-B1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | SERVIER LAB (FR) | 2006-12-20 | — | — | EP | disclosed |
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| EP-1502590-A1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | Les Laboratoires Servier (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-20040116708-A1 | Insulin sensitizers; antidiabetic agents, antiinflammatory agents; inflammatory bowel disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375484-A1 | CARBOXYLIC ACIDS | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | POLB 886/4885GAA 628/4885CYP3A4 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.